Brief: Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
23/09/2024 14:12
Sept 23 (Reuters) - Bioatla Inc BCAB.O :
* BIOATLA AND CONTEXT THERAPEUTICS ANNOUNCE EXCLUSIVE
WORLDWIDE
LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE BA3362, A
NECTIN-4 X CD3 T CELL ENGAGING ANTIBODY
* CONTEXT THERAPEUTICS INC - BIOATLA TO RECEIVE $15 MILLION
UPFRONT, UP TO $118.5 MILLION IN MILESTONES
* CONTEXT THERAPEUTICS INC - ANTICIPATES IND FILING FOR
BA3362 IN
MID-2026
Source text for Eikon: ID:nGNX6nwnt3
Further company coverage: BCAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202